<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5673">
  <stage>Registered</stage>
  <submitdate>27/01/2014</submitdate>
  <approvaldate>27/01/2014</approvaldate>
  <nctid>NCT02048514</nctid>
  <trial_identification>
    <studytitle>The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms</studytitle>
    <scientifictitle>The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N09-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Abdominal Aortic Aneurysms</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - The Nellix® EndoVascular Aneurysm Sealing System

Experimental: Nellix Aneurysm Sealing - The Nellix® EndoVascular Aneurysm Sealing System


Treatment: devices: The Nellix® EndoVascular Aneurysm Sealing System


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety - The primary safety endpoint is defined as the incidence of Major Adverse Events (MAE) through 30 days after the index procedure.</outcome>
      <timepoint>30 day</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Device Performance - The primary performance endpoint is technical success defined as successful delivery and deployment of the device and freedom from open surgical conversion at 30 days.</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All Cause Mortality - Any death occurring during the study period, regardless of cause</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age

          -  Informed consent form understood and signed and patient agrees to all follow-up visits

          -  Is able and willing to comply with clinical follow-up requirements for one year

          -  Is able and willing to undergo Contrast-Enhanced Spiral CT scans

          -  Is a candidate for endovascular repair of an infrarenal aortic aneurysm with or
             without an iliac aneurysm with at least one of the following;

               1. aneurysm = 4.5 cm in diameter, or

               2. aneurysm is twice the diameter of the normal infrarenal aorta, or

               3. aneurysm is growing at a rate of = 10 % per year

          -  Non-aneurysmal aortic neck length = 5mm below the most inferior renal artery

          -  Proximal aortic neck diameter between 16 and 36mm

          -  Aortic neck angulation to the sac = 60

          -  Common iliac artery diameter 8 to 35mm bilaterally

          -  Aneurysm blood lumen diameter = 60mm

          -  Iliac and femoral arteries suitable for endovascular access with the Nellix System</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Life expectancy = 1 year

          -  Dissecting, ruptured, or leaking aneurysm (blood outside the aorta), has sustained
             recent trauma, is symptomatic, or is non-degenerative

          -  Aneurysm is thoraco-abdominal, suprarenal and/or mycotic

          -  Thoracic aneurysm = 4.5cm in diameter

          -  AAA requires treatment that would result in bilateral occlusion of the internal iliac
             arteries

          -  Presence of mural thrombus &gt; 50% circumferentially in aortic neck

          -  Iliac aneurysm blood lumen diameter &gt; 35mm

          -  Active infection, vasculitis, or systemic connective tissue disease (e.g., Rheumatoid
             arthritis, scleroderma, Marfan's syndrome, Ehlers-Danlos disease) at time of procedure

          -  History of prior treatment of abdominal aortic or iliac artery aneurysm disease

          -  Femoral or iliac artery occlusive disease such that device delivery is not possible

          -  Vascular access for delivery of device requires placement of vascular conduit or is
             through an established vascular graft

          -  Receiving dialysis

          -  History of hypercoagulability

          -  Allergy to IV contrast

          -  Serum creatinine level &gt;2.0 mg/dL (or equivalent)

          -  Patient is pregnant or nursing

          -  Patient is currently enrolled in an investigational drug or device trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>69</actualsamplesize>
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Venezuela</country>
      <state>Caracas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Endologix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this clinical study is to evaluate the safety and device performance of the
      Nellix® EndoVascular Aneurysm Sealing System (Nellix System) for the treatment of infrarenal
      abdominal aortic aneurysms.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02048514</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>